ACM  >> Vol. 3 No. 1 (March 2013)

    以基因型为导向治疗改变了转移性非小细胞肺癌治疗模式
    The Genotype-Oriented Therapy Changed the Therapy Mode of Metastatic NSCLC

  • 全文下载: PDF(170KB) HTML   XML   PP.5-9   DOI: 10.12677/ACM.2013.31002  
  • 下载量: 1,788  浏览量: 6,904  

作者:  

李 娟,朱步东:北京大学肿瘤医院日间病房,北京;
张力建:北京大学肿瘤医院胸外科,北京肿瘤医院北京市肿瘤防治研究所,恶性肿瘤发病机制及转化研究教育部重点实验室,北京;
王跃辉:吉林省四平市肿瘤医院,四平

关键词:
非小细胞肺癌治疗 Non-Small Cell Lung Cancer (NSCLC); Therapy (Treatment)

摘要:

随着肿瘤驱动基因与临床关系的认识深化,转移性非小细胞肺癌(non-small cell lung cancer, NSCLC)的治疗模式发生了革命性变化,患者的生存得益显著改善。治疗模式由过去的化疗过渡到基因型导向结合化疗治疗模式。与此同时,维持治疗、二线治疗、免疫化学(特别是抗体)治疗的临床研究活跃。作者阐述和分析了上述NSCLC治疗现状和进展。

With the deepening acknowledge on the relation between tumour driver genomes and clinical treatment, NSCLC therapy has revolutionary changed. So this kind of patients could survive more comfortably. The treatment mode changed from chemotherapy to the combining treatment of genotype-oriented and chemotherapy. Meanwhile, the clinical researches of maintenance treatment, second-line treatment, immunochemistry (especially the antibody) treatment carried out vibrantly. The author expounds and analyzes the current situation and progress in NSCLC treatments.





文章引用:
李娟, 张力建, 王跃辉, 朱步东. 以基因型为导向治疗改变了转移性非小细胞肺癌治疗模式[J]. 临床医学进展, 2013, 3(1): 5-9. http://dx.doi.org/10.12677/ACM.2013.31002

参考文献

[1] T. S. Mok, Y. L. Wu, S. Thongprasert, et al. Gefitinib or carbopla-tin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 2009, 361(10): 947-957.
[2] M. Fukuoka, Y. L. Wu, S. Thongprasert, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/ paclitaxel in clinically selected patients with advanced non- small-cell lung cancer in Asia (IPASS). Journal of Clinical Oncology, 2011, 29(21): 2866-2874.
[3] T. Mitsudomi, S. Morita, Y. Yatabe, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncology, 2010, 11(2): 121-128.
[4] M. Maemondo, A. Inoue, K. Kobayashi, et al. Gefitinib or che-motherapy for non-small-cell lung cancer with mutated EGFR. New England Journal of Medicine, 2010, 362(25): 2380-2388.
[5] S. Oizumi, K. Kobayashi, A. Inoue, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: Quality of life analysis of north east Japan study group 002 trial. Oncologist, 2012, 17(6): 863-870.
[6] R. S. Herbst, D. Prager, R. Hermann, et al. TRIBUTE: A phase III trial of erlotinib (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology, 2005, 23(25): 5892-5899.
[7] U. Gatzemeier, A. Pluzanska, A. Szczesna, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The tarceva lung cancer investigation trial. Journal of Clinical Oncology, 2007, 25(12): 1545-1552.
[8] S. Morita, I. Okamoto, K. Kobayashi, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clinical Cancer Research, 2009, 15(13): 4493-4498.
[9] F. R. Hirsch, R. S. Herbst, C. Olsen, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. Journal of Clinical Oncology, 2008, 6(20): 3351-3357.
[10] J. V. Heymach, L. Paz-Ares, F. De Braud, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology, 2008, 26(33): 5407-5415.
[11] G. Goss, F. A. Shepherd, S. Laurie, et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gem-citabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer, 2009, 45(5): 782-788.
[12] D. D. Karp, L. G. Paz-Ares, S. Novello, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small- cell lung cancer. Journal of Clinical Oncology, 2009, 27: 2516- 2522.
[13] M. Reck, J. von Pawel, P. Zatloukal, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. Journal of Clinical Oncology, 2009, 27(8): 1227-1234.
[14] H. Wakelee. Antibodies to vascular endothelial growth factor in non-small cell lung cancer. Journal of Thoracic Oncology, 2008, 6(Suppl. 2): S113- S118.
[15] L. Paz-Ares, F. de Marinis, M. Dediu, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncology, 2012, 13(3): 247-255.
[16] R. Porta, J. M. Sánchez-Torres, L. Paz-Ares, et al. Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation. European Respiratory Journal, 2011, 37(3): 624-631.